Diagnostic and therapeutic appropriateness in different stages of esophageal/GEJ cancers. The FICOG project.

IF 2.6 4区医学 Q2 ONCOLOGY

Future oncology Pub Date : 2025-10-01 Epub Date: 2025-09-09 DOI:10.1080/14796694.2025.2551482

Carmine Pinto, Carlo Castoro, Ferdinando De Vita, Alberto Gianluigi Luporini, Evaristo Maiello, Renzo Mazzarotto, Aldo Scarpa, Riccardo Caccialanza, Angela Damato

{"title":"Diagnostic and therapeutic appropriateness in different stages of esophageal/GEJ cancers. The FICOG project.","authors":"Carmine Pinto, Carlo Castoro, Ferdinando De Vita, Alberto Gianluigi Luporini, Evaristo Maiello, Renzo Mazzarotto, Aldo Scarpa, Riccardo Caccialanza, Angela Damato","doi":"10.1080/14796694.2025.2551482","DOIUrl":null,"url":null,"abstract":"Background: Esophageal cancer is a rare neoplasm, with more than 0.6 million new cases and 0.54 million deaths worldwide in 2020. The distal third of the esophagus and the gastroesophageal junction (GEJ) are mostly involved sites. The diagnosis and therapeutic management of early, locally advanced, and metastatic disease continue to present uncertainties, as existing guidelines may not fully address all clinical questions in these areas.Methods: A group of Italian Experts produced recommendations for early, locally advanced, and metastatic disease management using the RAND/UCLA Appropriateness Method. Statements were generated by a systematic revision of the literature and voted on twice by a panel of 29 expert physicians; the second vote took place during a meeting of the panelists.Results: Several topics covered diagnosis, staging, treatment, and early, localized, and metastatic disease management. Recommendations were stated.Conclusions: Interventions considered appropriate to improve compliance and outcomes of esophageal/GEJ cancer patients were identified.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"3027-3041"},"PeriodicalIF":2.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12492973/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2551482","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/9 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Esophageal cancer is a rare neoplasm, with more than 0.6 million new cases and 0.54 million deaths worldwide in 2020. The distal third of the esophagus and the gastroesophageal junction (GEJ) are mostly involved sites. The diagnosis and therapeutic management of early, locally advanced, and metastatic disease continue to present uncertainties, as existing guidelines may not fully address all clinical questions in these areas.

Methods: A group of Italian Experts produced recommendations for early, locally advanced, and metastatic disease management using the RAND/UCLA Appropriateness Method. Statements were generated by a systematic revision of the literature and voted on twice by a panel of 29 expert physicians; the second vote took place during a meeting of the panelists.

Results: Several topics covered diagnosis, staging, treatment, and early, localized, and metastatic disease management. Recommendations were stated.

Conclusions: Interventions considered appropriate to improve compliance and outcomes of esophageal/GEJ cancer patients were identified.

查看原文本刊更多论文

食管癌/食管贲门癌不同分期诊断和治疗的适宜性。FICOG项目。

背景：食管癌是一种罕见的肿瘤，2020年全球将有60多万新发病例和54万死亡病例。食管远端三分之一和胃食管交界处（GEJ）是主要受累部位。早期、局部晚期和转移性疾病的诊断和治疗管理仍然存在不确定性，因为现有指南可能无法完全解决这些领域的所有临床问题。方法：一组意大利专家提出了使用RAND/UCLA适当方法进行早期、局部晚期和转移性疾病管理的建议。声明是通过对文献的系统修订产生的，并由29名专家医生组成的小组进行了两次投票；第二次投票在小组成员会议期间进行。结果：几个主题涵盖了诊断、分期、治疗、早期、局部和转移性疾病的管理。提出了建议。结论：确定了适当的干预措施，以提高食管癌/GEJ癌患者的依从性和预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.